Why Virpax Pharmaceuticals Stock Flying Higher?

by Vandana Singh, Benzinga Editor

August 17, 2021 9:59 AM | 1 min read |

Virpax Pharmaceuticals Inc VRPX has received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.
The drug candidate is a high-density molecular masking spray under development for use as an anti-viral barrier product.
Virpax plans to pursue prophylactic treatment against SARS and influenza for daily use as an OTC product.
The Company has engaged Syneos Health to assist with the optimal clinical trial design.
Price Action: VRPX shares are trading 132.1% higher at $9.76 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.